NCT00397176已完成1 期
Ascending, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of DVS SR Administered Orally to Healthy Japanese Female Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 32 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 主要终点
- Safety, Tolerability, PK
研究概览
简要总结
Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy, first-generation (born in Japan, living in the US for less than 5 years)
- •Japanese female subjects
排除标准
- 未提供
结局指标
主要结局
Safety, Tolerability, PK
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDDDepressive Disorder, MajorNCT00445679Wyeth is now a wholly owned subsidiary of Pfizer807
已完成
3 期
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With MenopauseHot FlashesSleep DisordersMenopauseNCT00256685Wyeth is now a wholly owned subsidiary of Pfizer568
已完成
1 期
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release TabletMajor Depressive DisorderNCT01443208Pfizer36
已完成
3 期
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal WomenVasomotor SymptomsNCT00683800Pfizer2,186
已完成
3 期
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive DisorderMajor Depressive DisorderNCT01309542Pfizer1,403